Skip to search formSkip to main contentSkip to account menu

MM-093

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Gateways to clinical trials.
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC… 
Review
2007
Review
2007
MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.
  • E. Dudich
  • Current opinion in molecular therapeutics
  • 2007
  • Corpus ID: 9338696
Merrimack Pharmaceuticals Inc (previously Atlantic Biopharmaceuticals) is developing MM-093 (formerly ABI-001), an injectable… 
2007
2007
A randomised, double-blind, placebo-controlled trial of a recombinant version of human α-fetoprotein (MM-093) in patients with active rheumatoid arthritis
Background: Rheumatoid arthritis (RA) tends to remit during pregnancy, with more patients achieving remission in the third… 
2007
2007
COX-2 inhibitor use in the Women's Health Initiative trials: re-analysis of the data
  • Nature Clinical Practice Rheumatology
  • 2007
  • Corpus ID: 37188672
MM-093 significantly improved the mean disease activity score (DAS) 28 and the mean patient’s global assessment compared with… 
2007
2007
The use of antimalarial agents might confer an anti-cancer effect in patients with SLE
  • Nature Clinical Practice Rheumatology
  • 2007
  • Corpus ID: 39784635
MM-093 significantly improved the mean disease activity score (DAS) 28 and the mean patient’s global assessment compared with… 
2007
2007
Gateways to clinical trials.
1-Octanol, 9vPnC-MnCc; Abiraterone acetate, Adalimumab, Adefovir dipivoxil, Alemtuzumab, Aliskiren fumarate, Aminolevulinic acid… 
2005
2005
A randomized double-blind, placebo-controlled trial of MM-093, a recombinant version of human alpha-fetoprotein, in patients with active rheumatoid arthritis (RA)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License